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SUMMARY  
Gliomas comprise heterogeneous malignant glial and stromal cells. While blood vessel co-option 
is a potential mechanism to escape anti-angiogenic therapy, the relevance of glial phenotype in 
this process is unclear. We show that Olig2+ oligodendrocyte precursor-like glioma cells invade 
by single-cell vessel co-option and preserve the blood-brain-barrier (BBB). Conversely, Olig2-
negative glioma cells form dense perivascular collections, promote angiogenesis and BBB 
breakdown leading to innate immune cell activation. Experimentally, Olig2 promotes Wnt7b 
expression, a finding that correlates in human glioma profiling. Targeted Wnt7a/7b deletion or 
pharmacologic Wnt inhibition blocks Olig2+ glioma single-cell vessel co-option and enhances 
responses to temozolomide. Finally, Olig2 and Wnt7 become upregulated after anti-VEGF 
treatment in preclinical models and patients. Thus, glial-encoded pathways regulate distinct 
glioma vascular-microenvironmental interactions.   
 
Keywords: glioma, vessel co-option, angiogenesis, Olig2, oligodendrocyte precursor, p53, Wnt, 
brain tumor, invasiveness, astrocyte, blood-brain-barrier, microglia/macrophage. 
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SIGNIFICANCE 
Although malignant glioma employs angiogenesis, anti-vascular endothelial growth factor 
(VEGF) inhibitors have failed to improve glioblastoma patient survival. We investigated whether 
a ‘glial code’ underlies glioma-vascular interactions. We find that Olig2+ oligodendrocyte 
precursor-like (OPCL) cells invade the parenchyma by single-cell vessel co-option and do not 
affect the underlying vasculature. In distinction, Olig2- gliomas grow as perivascular clusters, 
leading to disruption of the blood-brain-barrier and innate immune cell activation. We show that 
Wnt7 expression in OPCL cells is needed for vessel co-option and that Wnt inhibition enhances 
the response to temozolomide therapy. Finally, anti-VEGF treatment selects for the Olig2/Wnt7+ 
glial phenotype providing insight into potential mechanisms underlying glioma escape from anti-
angiogenic therapy.    
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INTRODUCTION 
About 25 000 individuals/year in the US are diagnosed with glioblastoma (GBM), a 
leading cause of cancer-related death (Ostrom et al., 2015). Gliomas typically escape 
microscopic surgical resection and recur because of their ability to invade diffusely into brain 
parenchyma (Olar and Aldape, 2014; Prados et al., 2015). GBMs have high metabolic 
requirements and use multiple mechanisms to ensure adequate access to the vasculature, 
including angiogenesis, vasculogenesis and trans-differentiation into endothelial cells (Boer et 
al., 2014; Carmeliet and Jain, 2011; Hu et al., 2016). In the distinct process of vessel “co-
option”, glioma cells invade the brain along the pre-existing vasculature (Jain, 2014). Although 
inhibitors of vascular endothelial growth factor (VEGF) have been proven to control edema and 
prolong progression-free survival in glioma patients (Chinot et al., 2014; Gilbert et al., 2014; 
Wick et al., 2017), these tumors become resistant to anti-VEGF treatment (Lu-Emerson et al., 
2015), by deploying alternative pathways and growth patterns. Indeed, both newly diagnosed and 
recurrent gliomas appear to exploit vessel co-option as a mechanism of escape from anti-
VEGF/R2 treatment (di Tomaso et al., 2011; Keunen et al., 2011; Rubenstein et al., 2000).  
In common with other cancers, gliomas can migrate either as single-cells along blood 
vessels or collectively as perivascular groups of cells (Te Boekhorst and Friedl, 2016) and this 
has implications for invasion of the brain and maintenance of the blood-brain-barrier (BBB) 
(Watkins et al., 2014). However, the cellular and molecular mechanisms that regulate glioma co-
option are poorly understood. One possibility is that glioma cell plasticity enables use of 
different vascular strategies depending on microenvironmental or treatment circumstances. 
Indeed, gliomas are highly heterogeneous tumors that show features of stem cells, 
oligodendrocyte precursors, astrocytes and oligodendrocytes (Patel et al., 2014). Olig2 – 
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expressed in almost all glioma subtypes (Ligon et al., 2004) – has multiple functions, including 
regulation of stem cell identity (Suva et al., 2014), tumor cell proliferation (Ligon et al., 2007) 
and oligodendrocyte versus astrocyte phenotype (Mehta et al., 2011). Moreover, these roles 
depend on the genetic context, as a critical function of Olig2 is antagonism of p53 activity (Sun 
et al., 2011). While Olig2 status may not be useful in determining clinical prognosis, it has been 
proposed as a direct therapeutic target (Mehta et al., 2011) through inhibitors that prevent 
phosphorylation needed for its pro-tumorigenic activities (Zhou et al., 2017).  
Oligodendrocyte precursors (OPCs), expressing Olig2, Nkx2.2, PDGFRDNG2 and other 
markers (Gallo and Deneen, 2014), can serve as tumor progenitors in adult high-grade glioma 
and oligodendroglioma (Liu et al., 2011; Persson et al., 2010). OPC-encoded Wnt7 signaling 
instructs white matter vascularization (Yuen et al., 2014), and Wnt-CXCR4 signaling regulates 
extensive OPC migration along the embryonic CNS vasculature (Tsai et al., 2016). In contrast, 
astrocytes migrate in a pattern restricted by the trajectory of their radial glial precursors (Tsai et 
al., 2012). Astrocytes have reduced proliferative potential compared with OPCs, but carry out 
other important roles such as regulation of vascular flow and maintenance of the BBB through 
tight junctions with endothelial cells (Zhao et al., 2015). Although glial cells encode distinct 
regulatory pathways to achieve normal vascular function in the developing brain, a systematic 
assessment of glial subtype roles in glioma has not been carried out. Here we addressed this 
question with a focus on tumor-stromal/vascular regulation.  
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RESULTS  
Olig2+ glioma cells invade the brain by single-cell vessel co-option. To determine vessel 
regulatory functions of OPC-like (OPCL) cells in glioma, we used an EGFRvIII-driven murine 
model that lacks p53 function (Figure 1A) and allows for variation in Olig2 functional status 
(Mehta et al., 2011). Olig2cre/+;Trp53fl/fl;hEGFRvIII (Olig2+) gliomas showed prevalent OPCL 
cells that expressed Olig2, PDGFRDand NG2 (Figure S1A-C), whereas 
Olig2cre/cre;Trp53fl/fl;hEGFRvIII (Olig2-) tumors expressed astrocyte markers, such as glial 
fibrillary acidic protein (GFAP). Although Olig2+ tumors developed more quickly than Olig2- 
tumors (Mehta et al., 2011), no preference in the tumor location (e.g., ventrally or dorsally) or 
size was observed and the proliferative index was not significantly different between the two 
types (Figure S1D); unsupervised hierarchical clustering analysis of Olig2+ versus Olig2- tumors 
demonstrated clear differences between the two types (Figure S1E). 2551 genes were 
differentially expressed including genes involved in glial differentiation (Table S1), and Olig2+ 
tumors showed an enrichment of OPCs versus astrocytic genes (Figure 1B and Table S2)(Zhang 
et al., 2014). We compared gene expression in Olig2+ and Olig2- mouse tumors with human 
oligodendroglioma and subtypes of GBM (Tirosh et al., 2016; Verhaak et al., 2010; Wang et al., 
2017). As shown (Figure S1F, 1G, Table S2), clustering analysis of differentially upregulated 
genes in Olig2+ (versus Olig2-) tumors indicated strongest association with human 
oligodendroglioma and proneural GBM gene profiles.   
We next investigated the vascular relationships of Olig2+ versus Olig2- gliomas. As 
shown by tumor-specific hEGFR labeling (Figure 1C, 1D), Olig2+ gliomas at the leading edge 
showed discrete single glioma cells extending from the tumor mass. In contrast, Olig2- tumor 
cells extended as dense perivascular collections. While Olig2+ tumors showed nearly normal 
7 
 
vasculature, the microvessel density (MVD), vessel size and the vascular and lumen areas within 
Olig2- gliomas were significantly increased (Figure 1E, 1F), which correlated with increased 
endothelial Slc2a1 expression (Figure S1H). Additionally, Olig2- glioma had defects in the 
vascular basement membrane, as shown by the decreased vascular Collagen IV expression 
(Figure 1G). We did not see evidence for trans-differentiation of hEGFRvIII+ tumor cells into 
endothelial cells regardless of Olig2 status (Figure S1I). These findings indicate that OPCL cells 
in glioma invade the brain by single-cell vessel co-option that minimally affects structure of the 
underlying stromal vasculature.    
Loss of BBB integrity, microglial activation and macrophage infiltration in Olig2-null 
gliomas. We further characterized BBB integrity in Olig2+ and Olig2- gliomas. BBB leakage 
causes macrophages infiltration (Bardehle et al., 2015) and migration and activation of resident 
microglia, which retract their processes and have an amoeboid appearance with an enlarged soma 
size (Kozlowski and Weimer, 2012). Fibrinogen (FBG) leakage into brain parenchyma is a 
potent inflammatory stimulant of resident microglia (Bardehle et al., 2015; Petersen et al., 2017). 
As shown (Figure 1I, 1J), Olig2- gliomas showed marked FBG leakage from blood vessels as 
well as increased expression of Plasmalemma Vesicle Associated Protein (Plvap), confirming 
loss of BBB integrity (Figure S1J). While we found increased numbers of Iba1+ microglial cells 
in both Olig2+ and Olig2- tumors versus normal brain, Olig2- tumors contained significantly 
higher numbers of ‘amoeboid’ microglia (Figure 1I, 1J, Figure S1K). Expression of macrophage-
specific genes (Bennett et al., 2016; Lavin et al., 2014; Venteicher et al., 2017) indicated 
significant infiltration of macrophages expressing F13a1, Ifitm2/3, Npc2 and Tgfb1 in Olig2- 
relative to Olig2+ gliomas (Figure 1H). Since these markers distinguish infiltrating macrophages 
from brain-resident microglia, this result also confirms BBB disruption in Olig2- glioma. We 
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conclude that Olig2+ glioma cells migrate as single-cells along a normal-appearing vasculature; 
in contrast Olig2- glioma cells grow as dense perivascular collections and disrupt astrocyte end-
feet (Watkins et al., 2014), resulting in BBB leakage and neuroinflammation.  
Wnt7a/7b function is essential for Olig2+ glioma single-cell co-option. The increased vessel 
density in Olig2- gliomas indicated that these tumors were relatively angiogenic. To further 
investigate distinct vascular features of Olig2+ versus Olig2- tumors, we compared the expression 
of a panel of known regulatory factors. As shown (Figure 2A), Olig2+ glioma showed higher 
levels of Wnt7a, Wnt7b and Lef1. OPCL tumor cells (hEGFR+, Nkx2.2+) expressed Wnt7 
proteins and abutted Lef1+, E-catenin+ blood vessels (Figure S2A, S2B), indicating a Wnt-active 
state in Olig2+ gliomas. In contrast, Olig2- tumors expressed higher levels of Vegfc and 
Vegfr1/2/3. Gene ontology analysis (Table S1) revealed that angiogenesis was the second most 
upregulated process in Olig2- tumors (Figure S2C) and such tumors showed increase in Ki67+ 
proliferating endothelial cells (Figure 2B). We did not observe significant differences in markers 
for lymphatics within the tumor (Figure S2D, S2E).  
 To establish cell-intrinsic roles for Wnt7 function in Olig2+ glioma, we first analyzed 
single-cell co-option in organotypic cortical explant co-cultures with glioma progenitors that 
carried the same hEGFRvIII and Trp53 mutations as above, in addition to knockout of Wnt7a 
and conditional deletion of Wnt7b. As shown (Figure 2C), Olig2+ cells with intact Wnt7 function 
employed single-cell co-option of blood vessels; video microscopy showed cells tugging the 
endothelium at their trailing edge, indicating direct contact (Movie S1 and Figure S2F). In 
contrast, Wnt7a/7b-null glioma cells failed to directly migrate on vessels. We also observed 
dramatic in vivo differences in which Wnt7a/7b-null cells migrated as perivascular collections 
rather than discrete/individual cells (Figure 2D, E). Similar to Olig2- tumors (Figure 1E) Olig2+, 
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Wnt7a/7b-null gliomas showed markedly abnormal vasculature (Figure 2F, G). These findings 
indicate a critical role for cell-intrinsic Wnt7 signaling in regulating single-cell versus collective 
migration in Olig2+ glioma cells (Figure 2H). 
Olig2 regulates Wnt7 expression in a p53-dependent manner. We investigated direct Olig2 
regulation of Wnt7 expression by chromatin immunoprecipitation (ChIP) and biochemical 
approaches. Based on previously published ChIP-seq analysis (Mateo et al., 2015; Mehta et al., 
2011; Tonelli et al., 2015), we identified two putative p53 binding sites at the Wnt7b locus near 
the transcription start site and ~50 kb upstream, and one Olig2 binding site ~30 kb upstream of 
the Wnt7b locus (Figure 3A). Loss of Olig2 function resulted in significantly higher p53 
occupancy at the Wnt7b locus; conversely, in Trp53-/- cells Olig2 binding was enriched (Figure 
3B, C). Loss of Trp53 resulted in a 6-fold increased Wnt7b transcript level, suggesting that 
Olig2-driven upregulation of Wnt7b is inhibited by p53 (Figure 3D). In order to confirm this 
antagonism, we showed that using DNA-binding mutant of Olig2DBM (Mehta et al., 2011; Meijer 
et al., 2014) p53 binding on Wnt7b was increased (Figure 3E). In addition, we demonstrated that 
the binding site of Olig2 within Wnt7b is functional as DBM failed to regulate Wnt7 expression, 
as well as Sox2 and Pdgfra (Figure 3F). To confirm these findings, we treated Cdkn2a-/-
;hEGFRvIII cells with 0.25 µM of Nutlin, which induces p53 stabilization. Nutlin treatment 
resulted in an increase in Cdkn1a expression, as expected (Mehta et al., 2011; Vassilev et al., 
2004), and a decrease in the expression of Wnt7b (Figure 3G), confirming that p53 represses 
Wnt7b expression. Olig2 can recruit chromatin-remodeling factors at enhancers and shift them 
from a latent inactive state to an active state (Yu et al., 2013). Indeed, in Trp53-/- cells we found 
strong enrichment of the active enhancer mark H3K27ac at the Wnt7b locus (Figure 3H). These 
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findings indicate that p53 can directly repress Wnt7b, whereas Olig2 promotes Wnt7b expression 
especially in gliomas that are Trp53-/- (Figure 3I). 
WNT7 expression correlates with OPC markers in human glioma. To confirm the relevance 
of Wnt7 signaling in human glioma we investigated the relationship of OPC markers and WNT7 
expression in The Cancer Genome Atlas (TCGA) database (Brennan et al., 2013). As shown 
(Figure 4A, 4B, Figure S3A and Table S3), we observed a strong positive correlation of OPC 
markers (OLIG2, NKX2.2, PDGFRA) with WNT7B mRNA levels in high-grade 
oligodendroglioma (OD) and proneural GBM. Consistent with our molecular model (Figure 3I), 
the correlation between OLIG2 levels and WNT7B was significantly stronger in TP53 mutant 
gliomas versus TP53 WT glioma (Figure 4C). In contrast, WNT5A and all other Wnt genes 
lacked positive correlation (Figure S3A). We also investigated stem cell markers (e.g., CD133, 
ABCG2 and ITGA6), but we only found a link of ABCG2 with OLIG2 specifically in OD, and no 
correlation with WNT7B (Figure S3B). To investigate gene expression in glioma cells per se 
(versus stromal tissue), we took advantage of single-cell transcriptomic profiling (Venteicher et 
al., 2017) of IDH mutant oligodendroglioma (IDH-O) and astrocytoma (IDH-A). This analysis 
showed that WNT7A expression was detected only in a minority (3.7%) of glioma cells, whereas 
WNT7B was expressed by 59% of glioma cells. To confirm Wnt7 expression in human gliomas, 
we used Western blot, qPCR (Figure S3C, D) and immunohistochemistry (Figure 4D-H and 
Figure S3E, F). Analysis of IDH-O revealed that Olig2+ tumor cells abutted blood vessels 
(Figure 4D-F) and we confirmed Olig2/Wnt7+ cells adjacent to blood vessels in several 
proneural GBM cases (Figure 4G, H, Figure S3F). Stromal vessels within high-grade OD and 
proneural GBMs showed endothelial expression of Lef1 and Tcf4, suggesting a Wnt-activated 
state (Figure 4I-K, Figure S3G).  
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Inhibition of canonical Wnt signaling prevents glioma single-cell co-option. We next 
investigated a genetically faithful mouse model of high-grade GBM, which carries hEGFRvIII 
and deletion of Cdkn2a (Bachoo et al., 2002; Ligon et al., 2007). Such tumor cells expressed 
Wnt7a/b and contained abundant Olig2+ cells that showed single-cell co-option in vivo (Figure 
5A, B). Similar to the above findings (Figure S2B), Lef1, in this model marks the endothelium 
but not the tumor itself, so we used the canonical Wnt inhibitor XAV939 (Fancy et al., 2011) to 
inhibit the endothelial response (Figure 5C). Time-lapse video confocal imaging revealed that 
untreated GFP-labeled glioma cells used single-cell migration along the vasculature (Figure 5D, 
E and Movies S2, 3). In contrast, XAV939-treated cells lost contact with vessels and formed 
clusters. We next investigated Wnt inhibition in a hypermutated recurrent IDH-O cell line 
expressing Wnt7a/b (Figure 5F). IDH-O cells were transplanted on slices and cultured in the 
presence of DMSO or the porcupine inhibitor LGK974 (Liu et al., 2013). Analysis of the 
percentage of cells contacting the vessels indicated a significant decrease after LGK974 
treatment (Figure 5G). These findings indicate that both canonical Wnt and porcupine inhibitors 
prevent glioma single-cell vessel migration.  
Systemic Wnt inhibition prevents single-cell co-option and improves survival with 
temozolomide treatment in a patient-derived proneural GBM model. We screened various 
glioma cell lines on the basis of Olig2 and Wnt7 expression. As shown (Figure 6A and Figure 
S4A, B), the proneural patient-derived cell line MGG8 (Suva et al., 2014; Wakimoto et al., 2012) 
expressed both Olig2 and Wnt7a proteins, in contrast to D54 cells that expressed Wnt7a but 
lacked Olig2. Using multi-photon intravital microscopy, we observed that both cell lines 
employed vessel co-option. However, D54 used collective migration, while MGG8 
predominantly employed single-cell migration. Based on these findings, we focused our analyses 
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on MGG8. As shown (Figure 6B and Figure S4C-E), 55 ± 2% of MGG8 cells contacted blood 
vessels and longitudinal imaging demonstrated that cells moved towards blood vessels (Figure 
S4C) forming close contacts with the Tie2P-GFP endothelium (Figure 6C). High-resolution 
imaging of MGG8 showed the well-described steps of 2D migration – extension, adhesion, 
translocation and de-adhesion (Figure 6D). Thus, MGG8 cells represent a suitable model of 
glioma single-cell vessel co-option, and this is consistent with previous findings where the 
vasculature of MGG8 tumors was shown to be similar to normal brain (Kloepper et al., 2016).  
To investigate Wnt signaling in vivo, we treated MGG8-bearing mice with LGK974 (Liu 
et al., 2013). Pharmacokinetic and IHC analyses showed that LGK974 crossed the BBB and 
reduced Wnt7a expression in vivo (Figure S5A, B). Systemic LGK974 treatment (5 mg/kg twice 
a day) significantly reduced the percentage of MGG8 cells in contact with blood vessels (Figure 
6E), indicating that glioma Wnt signaling is required for single-cell vessel co-option in vivo. 
Treatment of MGG8-GFP-GLuc-bearing mice at early stages of tumor development (around 4 
mm3) with 5 mg/kg of LGK974 once a day was well tolerated (Figure S5C, D) and showed a 
trend of improved survival (Figure S5E, p < 0.06). To better model the standard of care in glioma 
patients, we treated MGG8-GFP-GLuc tumor-bearing mice with LGK974 alone or in 
combination with temozolomide (TMZ) at a late stage of the disease. Using the serum GLuc 
(Kloepper et al., 2016), we started treatment when the tumor reached an approximate volume of 
about 9-10 mm3. LGK974 significantly improved survival when combined with TMZ of 20% in 
comparison with TMZ alone (Figure 6F). Thus, pharmacologic Wnt inhibition blocks Olig2+ 
glioma single-cell vessel co-option and enhances TMZ efficacy. 
Anti-VEGF or -Wnt treatments select for distinct glial phenotypes and vascular regulatory 
pathways in glioma. Clinical and experimental studies indicate that co-option in glioma is 
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promoted by prolonged treatment with VEGF inhibitors (di Tomaso et al., 2011). We next 
investigated Olig2 expression, VEGF and Wnt signaling under conditions of inhibitor treatment. 
As shown (Figure 7A, Figure S6A), addition of LGK974 to cultured MGG8 and MGG6 (another 
patient-derived proneural cell line) (Wakimoto et al., 2012) cells, resulted in a downregulation of 
OLIG2 and WNT7A and an upregulation of VEGFA. Conversely, the VEGF inhibitor B20 
treatment increased OLIG2 expression (Figure 7B, Figure S6B). In vivo, MGG8 tumor-bearing 
mice treated with LGK974 showed increased VEGF expression and microglial cell number 
(Figure 7C), whereas B20 antibody treatment showed a significant increase in Lef1 expression 
within the endothelial compartment of the tumors, indicating an increase in Wnt signaling 
(Figure 7D). These findings further support a model where Wnt and VEGF signaling are coupled 
to glial phenotype.  
To further test this idea, we chose the U87 cell line, which is Olig2- and grows as a mass 
reliant on angiogenesis and VEGF signaling (Peterson et al., 2016). We used a multi-
generational model with increasing resistance to Bev (Figure 7E), which has been shown to 
promote glioma vessel co-option (Jahangiri et al., 2013). As shown (Figure 7E, Figure S6C), we 
found that both Wnt7a and Wnt7b were upregulated in bevacizumab-resistant (BevR) U87 
compared to naive/sensitive BevS glioma cells. Moreover, this was associated with dramatically 
increased levels of Olig2 and Nkx2.2. Thus, even the entrenched astroglial U87 glioma line can 
select for an OPC phenotype in the context of multi-generational Bev treatment.  
To determine relevance of these findings in humans, we took advantage of a unique 
collection of five GBM paired samples taken at biopsy pre-treatment and post-mortem/post-
treatment with Bev. We found increased Wnt7a expression in post-Bev treatment tumor tissue in 
three of five samples (Figure 7F, Table S4); greater staining was noted at the infiltrative tumor 
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edge compared to the tumor core in one additional sample. Although further cases of Bev-treated 
GBM are needed to confirm this finding in humans, these results combined with the others above 
collectively suggest that OPC features and Wnt7 signaling are selected for by anti-VEGF therapy 
(Figure 7G).  
 
DISCUSSION 
Glioma cellular heterogeneity is used to adapt to environmental and genotoxic stress, enhance 
survival and promote invasiveness (Carmeliet and Jain, 2011). Since Olig2 is a master regulator 
of glial cell fate in development and glioma (Lu et al., 2002; Mehta et al., 2011), we reasoned 
that Olig2+ oligodendrocyte precursor-like (OPCL) and Olig2-negative “astrocyte-like“ cells 
could serve different functions in tumor growth and survival. We developed archetypal Olig2+ 
OPCL and Olig2-null glioma models and used expression profiling as a means of identifying the 
glial subtype-encoded molecular pathways relevant for vascular regulation. We found that OPCL 
cells in human glioma expressed Wnt7 and invaded the brain via single-cell vessel co-option. 
Gene targeting of Wnt7a/7b or pharmacological inhibition of Wnt prevented vessel contact of 
OPCL glioma cells. In contrast, Olig2- cells showed collective perivascular migration and 
enhanced VEGF signaling; this led to increased and distorted vasculature within the tumor and 
BBB leakage, in turn leading to microglial activation and macrophage infiltration. Interestingly, 
normal embryonic OPCs also express Wnt7a/7b and migrate along blood vessels (Tsai et al., 
2016), suggesting that glioma OPCL co-option uses mechanisms analogous to that for 
developmental spread of OPCs and possibly downstream Wnt signaling in the endothelium 
(Posokhova et al., 2015; Zhou and Nathans, 2014). Functions of glioma Wnt7a/7b revealed in 
our study are distinct from reported roles for other Wnts in endothelial trans-differentiation or 
angiogenesis (Hu et al., 2016; Reis et al., 2012), as we found no evidence for trans-
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differentiation in mouse or human IDH-mutant tumors by histology or gene expression 
(Venteicher et al., 2017). 
Mouse modeling of IDH mutation has impact on the microenvironment (Amankulor et 
al., 2017), and single-cell transcriptomic analysis of human tumors indicates that IDH-A (versus 
IDH-O) tumors show significantly more contribution of activated microglia and macrophage 
markers (Venteicher et al., 2017). This fits with our findings showing that Olig2-null (“astrocyte-
like”) gliomas have BBB breakdown, microglial and macrophage activation/infiltration. 
Moreover, this is consistent with a prior study that showed (Olig2-) D54 cells displacing stromal 
astrocyte end-feet leading to BBB leakage (Watkins et al., 2014). In contrast, Wnt7-expressing 
OPCL gliomas showed little microglial activation, these findings suggest that the tumor 
inflammatory microenvironment is regulated, at least in part by glial phenotype. However, 
further studies are needed to understand the mechanisms involved in the immune response (e.g. 
cytokines expression) as well as structural and/or cell-cell interactions that account for clinically 
relevant BBB properties in glioma. For example, Magnetic resonance (MR) and FLAIR imaging 
can reveal tumor margins by BBB leakage. Our findings suggest that OPCL glioma cells could 
invade the brain without any detectable MRI signature, and as such could lie beyond margins of 
surgical resection or a radiotherapy field. If so, interventions to visualize OPCL populations 
would be important to better define glioma therapeutic boundaries. Although OPCL glioma cells 
might use other signaling pathways, CNS-specific knockout of Wnt7a/b or endothelial cell-
specific deletion of Ctnnb1 causes severe leak and vessel breakdown (Daneman et al., 2009; 
Stenman et al., 2008; Tran et al., 2016) and as such would be reflected by MR imaging.   
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Previous studies have suggested that bevacizumab reduces edema and prolongs progression-free 
but not overall survival in newly diagnosed GBMs (Chinot et al., 2014; Gilbert et al., 2014) and 
progressive GBMs (Wick et al., 2017). Analysis of AVAglio, a randomized phase III clinical 
study that investigated the addition of bevacizumab to radiotherapy/TMZ, suggests that IDH1 
wild-type proneural versus mesenchymal GBMs may benefit (Sandmann et al., 2015). In 
contrast, the BELOB trial with recurrent GBMs showed that the classical subtype was most 
responsive to bevacizumab in combination with lomustine (Erdem-Eraslan et al., 2016). Thus, 
GBMs molecular subgroup may not be an adequate predictor of response to anti-angiogenic 
therapy and further criteria are needed.    
Vessel co-option has been proposed as an intrinsic or acquired resistance mechanism to 
anti-angiogenesis (Carmeliet and Jain, 2011; di Tomaso et al., 2011; Emblem and Jain, 2016; 
Frentzas et al., 2016; Pezzella and Gatter, 2015). Our findings indicate a “glial switch” and Wnt7 
signaling as targets in this regard because prolonged anti-VEGF therapy in a mouse model 
selected for strong upregulation of Olig2 and Wnt7. Our results indicate that glial phenotype is 
critical to provide the cellular context for Wnt7 activity in co-option (or VEGF in angiogenesis). 
For example, Olig2- glioma also expressed Wnt7a/7b, albeit at significantly lower levels, and 
show less single-cell co-option. Similarly, we show that D54 and U87 lines expressed Wnt7a or 
7b but did not show single-cell co-option owing to lack of OPCL (Olig2) character. Glial lineage 
regulators (e.g., Olig2, Sox10, NF1A, etc.) are expressed in glioma (Glasgow et al., 2014) and 
our study suggests that they are recruited to determine cell fate and, consequently, co-option and 
other modes of invasion (Osswald et al., 2015), as well as angiogenesis and regulation of the 
tumor microenvironment.   
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Finally, considering therapeutic implications, we show feasibility of LGK974 treatment 
to inhibit single-cell co-option of a proneural GBM patient-derived line in vivo and improve 
survival when combined with TMZ. LGK974, a porcupine inhibitor, crossed the BBB and 
prevented the secretion of Wnt7. These and other studies suggest targeting glioma WNT 
signaling might be clinically useful to promote BBB permeability and delivery of chemotherapy. 
For example, Phoenix et al. (2016) showed that medulloblastoma xenografts that express Wnt 
inhibitors have a leaky BBB, enhanced penetration of vincristine and a better therapeutic 
response. However, further investigation is needed to understand potential benefits of anti-Wnt 
signaling approaches in adjuvant therapy in other classes of patient-derived GBMs. In sum, our 
study provides mechanistic insights into the plasticity of glioma glial cells and the molecular 
strategies they encode to exploit their environment, especially in response to anti-angiogenic 
therapy.     
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FIGURE LEGENDS  
Figure 1. Olig2 function regulates vessel co-option and the tumor microenvironment.  
(A) Schematic of Olig2+ and Olig2- tumors generation from glioma progenitor cells (GPCs). 
(B) Heatmap (log2 fold change) of genes upregulated in Olig2+ versus Olig2- tumors (FDR 
adjusted p < 0.05) comparing murine oligodendrocyte precursor cells to astrocytes (Zhang et al., 
2014). 
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(C) Immunostaining for hEGFR at tumor borders in dorsal cortex. Right panels represent high 
magnifications of the boxed areas in left panels. Black arrowheads show single-cell migration (n 
= 6 per genotype). Scale bars, 200 μm left and 50 μm right.  
(D) Immunostaining for hEGFR and CD31 in Olig2+ and Olig2- tumors one month post-
transplantation. Right panels represent high magnifications of the boxed areas in left panels. 
White arrowheads show single-cell vessel co-option (n = 3 per genotype). Scale bars, 200 μm 
left and 50 μm right.  
(E, F) Immunostaining (E) and quantification (F) for CD31 and analysis of microvessel density 
(MVD), vessel size, percentage of vascular area and lumen area in normal brain, Olig2+ and 
Olig2- tumors. Data are mean ± s.e.m (n = 4-6 per genotype, ns: non-significant, *p < 0.05, **p 
< 0.01, ***p < 0.001, ****p < 0.0001). Scale bar, 200 μm.  
(G) Collagen IV (ColIV) and CD31 immunostaining in Olig2+ versus Olig2- tumors. Yellow 
arrowheads indicate absence of vascular basement membrane coverage. Data are mean ± s.e.m (n 
= 3 per genotype, ns: non-significant, ****p < 0.0001). Scale bar, 50 μm.  
(H) Fold change in macrophage markers expression using microarrays comparing Olig2+ versus 
Olig2- tumors. Data are mean ± s.e.m (n = 3 per genotype, ns: non-significant, *p < 0.05, **p < 
0.01, ****p < 0.0001).  
(I) Fibrinogen (FBG), Iba1 and CD31 immunostaining in Olig2+ and Olig2- tumors. White and 
yellow arrowheads indicate FBG leakage and microglial cells, respectively (n = 3 per genotype). 
Scale bar, 25 μm. 
(J) FBG integrated density of fluorescence in normal brains, Olig2+ and Olig2- tumors. 
Quantifications of Iba1+ cells perimeter and soma size in normal brains, Olig2+ and Olig2- 
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tumors. Data are mean ± s.e.m (n = 3 per genotype, ns: non-significant, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).  
See also Figure S1 and Table S2 
Figure 2. Wnt7 signaling regulates single-cell vessel co-option. 
(A) Quantitative PCR for vascular regulatory factors in Olig2+ versus Olig2- tumors. Rn18s and 
Actb were used as housekeeping genes. Data are mean ± s.e.m (n = 3 experiments).  
(B) Ki67 and CD31 immunostaining and quantifications in Olig2+ and Olig2- tumors. Data are 
mean ± s.e.m (n = 3 per genotype, ***p < 0.001). Scale bars, 20 μm. 
(C) Confocal live-imaging of Wnt7a/b WT and Wnt7a/b-null glioma progenitor cells (GPCs). 
Scale bars, 20 µm. 
(D) Immunostaining for hEGFR, Collagen IV and DAPI in Wnt7a/b WT and Wnt7a/b-null 
tumors (n = 3 per genotype). Scale bars, 250 µm (left) and 20 µm (right). 
(E) Quantification of the number of hEGFR per vessel in Wnt7a/b WT and Wnt7a/b-null tumors 
one month after transplantation. Data are mean ± s.e.m (n = 3 per genotype, ***p < 0.001).  
(F) Quantification of the microvessel density in Wnt7a/b WT and Wnt7a/b-null tumors at the 
time of neurological symptoms appearance. Data were normalized to microvessel density of the 
normal brain. Data are mean ± s.e.m (n = 3 per genotype, **p < 0.01).  
(G) CD31 immunostaining in Wnt7a/b WT and Wnt7a/b-null tumors (n = 3 per genotype). Scale 
bars, 20 µm. 
(H) Schematic summarizing the effects of genetic Wnt signaling inhibition on tumor cell 
migration and association to the vasculature.  
See also Figure S2 and Movie S1 
Figure 3. Olig2 function promotes Wnt7b expression in Trp53-/- glioma. 
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(A) Schematic of Olig2 and p53 binding sites within the Wnt7b locus.  
(B) ChIP experiments showing p53 binding at the Wnt7b locus. Cdkn1a was used as a known 
target for p53. Data are mean ± s.e.m (n = 3 per genotype, ns: non-significant, *p < 0.05, ***p < 
0.001, ****p < 0.0001). 
(C)  ChIP experiments showing Olig2 binding at the Wnt7b locus. Olig1 (+36 kb) was used as a 
known target for p53. Data are mean ± s.e.m (n = 3 per genotype, **p < 0.01, ***p < 0.001). 
(D) Quantitative PCR for Wnt7b.  Data are mean ± s.e.m (n = 3 per genotype, *p < 0.05). Rn18s 
and Actb were used as housekeeping genes.  
(E) ChIP assay for p53 distal and proximal responsive elements (RE) and Olig2 responsive 
elements (RE) at the Wnt7b locus using Olig2cre/cre cells transfected with WT and Olig2-binding 
mutant (DBM). Data are mean ± s.e.m (n = 3 per genotype, **p < 0.01, ***p < 0.001, ****p < 
0.0001). 
(F) Quantitative PCR using Olig2cre/cre cells transfected with WT and Olig2-binding mutant 
(DBM). Data are mean ± s.e.m (n = 3 per genotype, ***p < 0.001, ****p < 0.0001). Rn18s and 
Actb were used as housekeeping genes.  
(G) Quantitative PCR analysis of Cdkn2a-/-;hEGFRvIII cells treated with DMSO (control) or 
0.25 µM Nutlin for 16 hr. Data are mean ± s.e.m (n = 3 per genotype, *p < 0.05). Rn18s and 
Ctnnb1 were used as housekeeping genes.  
(H) ChIP assay for H3K27ac at Wnt7b promoter region using Olig2cre/cre cells transfected with 
WT and Olig2-binding mutant (DBM). Data are mean ± s.e.m (n = 3 per genotype, ns: non-
significant, ****p < 0.0001).  
(I) Regulatory model: p53 directly represses Wnt7b, whereas Olig2 indirectly promotes its 
expression.  
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Figure 4. WNT7 expression strongly correlates with OPC markers in human glioma. 
(A, B) Pearson correlation coefficients of OLIG2 and NKX2.2 with WNT7B mRNA levels in 
normal brain, glioblastoma (GBM), grade III oligodendroglioma (OD Gr.III) (A) and in GBM 
subtypes: classical (C), mesenchymal (M), neural (N), and proneural (PN) (B). n is indicated for 
each group (***p < 0.001). 
(C) Pearson correlation coefficients of OLIG2 with WNT7B mRNA levels in p53 wild-type and 
mutant grade III oligodendroglioma (OD). *p < 0.05.  
(D-F) Immunostaining for Idh1-R132 (D), Wnt7a, vWF, Olig2 (E) and Idh1-R132, Wnt7a, 
Wnt7b, Olig2 (F) on IDH1R132H-mutant grade III oligodendroglioma. Black arrowheads indicate 
tumor cells (n = 4 cases). Scale bars, 20 μm and 10 μm for low and high-magnifications pictures, 
respectively. 
(G-H) Immunostaining for Olig2, Wnt7b, Collagen IV (G) and Wnt7a, Olig2, CD31 (H) on 
proneural glioblastoma. Yellow arrowheads indicate Olig2+ Wnt7a+ cells (n = 3 cases). Scale 
bars, 20 μm and 10 μm for low and high-magnifications pictures, respectively. 
(I) Immunostaining for CD31, Lef1, Olig2 and Collagen IV on IDH1R132H-mutant grade III 
oligodendroglioma. White arrowheads indicate Lef1+ cells (n = 3 cases). Scale bars, 20 μm and 
10 μm for low and high-magnifications pictures, respectively. 
(J) Immunostaining for CD31 and Lef1 on proneural glioblastoma (PN GBM) samples. White 
arrowheads indicate Lef1+ cells (n = 3 cases). Scale bar, 20 μm. 
(K) Quantifications of the percentage of Lef1+ CD31+ cells in grade III oligodendroglioma (OD-
III) and proneural glioblastoma (PN GBM). Data are mean ± s.e.m (n = 3 cases per group). 
See also Figure S3 and Table S3 
Figure 5. Targeting canonical Wnt signaling prevents single-cell glioma co-option. 
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(A) Western Blot and densitometry analysis using protein lysates from Cdkn2a-/-;hEGFRvIII 
cells. Data are mean ± s.e.m (n = 2 lines with replicates).  
(B) Immunostaining for Olig2, hEGFR, CD31 and Lef1 using tumors three months post-
transplantation with Cdkn2a-/-;hEGFRvIII cells (n = 3 per genotype). Scale bars, 10 μm. 
(C) Schematic of Wnt signaling inhibition. 
(D) Confocal live-imaging of vehicle- and XAV939-treated Cdkn2a-/-;hEGFRvIII glioma 
progenitor cells (GPCs). Scale bars, 20 µm. 
(E) Quantifications of the number of cells contacting vessels relative to the total number of GFP+ 
cells (top) and of the distance travelled by the individual cells on the vessels (μm). Data are mean 
± s.e.m (n = 2 experiments with four fields quantified, p < 0.05, ****p < 0.0001). 
(F) Western Blot and densitometry analysis using IDH1R132H-mutated oligodendroglioma cell 
line (SF10417) under proliferation conditions at two different passages. Data are mean ± s.e.m 
(triplicates).  
(G) Slice culture experiments using IDH1R132H-mutated oligodendroglioma cell line (SF10417) 
in the absence (DMSO) or in the presence of LGK974 (1 µM) for 24 hr. Quantifications of the 
number of cells contacting the vessels relative to the total number of GFP+ cells. Data are mean ± 
s.e.m (n = 3 experiments, *p < 0.05). Scale bars, 20 µm. 
See also Movie S2 and Movie S3 
Figure 6. Systemic Wnt inhibition reduces vessel co-option and enhances temolozomide 
effect in patient-derived proneural GBM model.  
(A) Western blot and densitometry analysis on duplicates from cultured patient-derived cell lines 
(D54 and MGG8).  
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(B) Schematic of intravital imaging (IVM) procedure and 3D renderings of 20 μm-deep z-stacks 
of D54-GFP and MGG8-GFP cells by IVM. Vessels were visualized using TAMRA-Dextran. 
Scale bars, 50 µm and 25 µm (insets). 
(C) Intravital imaging of MGG8-mCherry cells implanted in Tie2P-GFP;Rag1-/- mice. Days in 
the legend are from intracranial transplantation. Insets are magnifications of the white dashed 
squares. Mean intensity projections of 24 μm-deep z-stacks. Scale bars, 100 µm and 50 µm 
(inserts). 
(D) Time-lapse IVM of a single-cell at the invasion front of MGG8 tumors 6 days after 
implantation. Vessels were visualized using TAMRA-Dextran. Mean intensity projections of 6 
μm-deep z-stacks. Scale bar, 10 µm. 
(E) 3D rendering of IVM images of tumors from vehicle- and LGK974-treated MGG8-bearing 
mice and quantification of the percentage of cells in contact with vessels. Data are mean ± s.e.m 
(n = 2 experiments, n = 9 mice for vehicle and n = 7 mice for LGK974, **p < 0.01). Scale bar, 
25 µm. 
(F) Kaplan-Meier analysis of MGG8-bearing mice treated with vehicle, temolozomide (TMZ), 
LGK974 and TMZ+LGK974. LGK974+TMZ (median survival = 24 days of treatment, n = 8) 
compared with TMZ (median survival = 20 days of treatment, hazard ratio (HR) 6.19, 95% 
confidence interval (CI) 1.62–23.63, **p = 0.008, n = 8), and vehicle (HR 18.45, 95% CI 4.3–
78.61, ***p = 0.0004, n = 9).  
See also Figure S4 and S5 
Figure 7. Wnt7 signaling is upregulated by anti-VEGF therapy. 
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(A) Quantitative PCR using vehicle and LGK974-treated MGG8 cells (100 mM LGK974 for 
three days). GAPDH was used as housekeeping gene. Data are mean ± s.e.m. (n = 2 experiments 
with technical triplicates, *p < 0.05, **p < 0.01, ***p < 0.001).  
(B) Quantitative PCR using IgG- and B20 (anti-VEGF)-treated MGG8 cells. GAPDH was used 
as housekeeping gene. Data are mean ± s.e.m. (n = 2 experiments with technical triplicates, *p < 
0.05).  
(C) VEGF and Iba1 immunostaining and quantification of 7 days vehicle and LGK974-treated 
MGG8 tumors. Black arrowheads indicate Iba1+ cells. Data are mean ± s.e.m (n = 3 mice per 
group, *p < 0.05, **p < 0.01). Scale bars, 10 µm. 
(D) B20 administration in MGG8-tranplanted animals for 10 days (10 mg/kg once a day i.p.). 
Lef1+ cells per vessels were quantified in IgG and B20 animals. Data are mean ± s.e.m (n = 6 
mice for IgG cohort and n = 16 mice for B20 cohort, *p < 0.05).   
(E) Model of progressive U87 glioma cell resistance. Western Blot and densitometry analysis 
using lysates from IgG-treated Bev-sensitive (BevS) and Bevacizumab-treated Bev-resistant 
(BevR) tumors. Data are mean ± s.e.m (n = 4 mice per genotype, *p < 0.05, **p < 0.01, ***p < 
0.001).  
(F) Human GBM paired samples taken at biopsy pre-treatment and post-mortem/post-treatment 
with Bev and stained for Wnt7a and Hematoxylin/Eosin. Black arrowheads indicate Wnt7a+ 
cells. Scale bar, 10 µm.  
(G) Schematic summarizing the effects of glial subtypes on vessel co-option and the tumor 
microenvironment, and their modulation upon VEGF and Wnt signaling inhibition.  
See also Figure S6 
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STAR METHODS 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, David H. Rowitch (dhr25@medschl.cam.ac.uk). 
EXPERIMENTAL MODELS AND HUMAN TISSUE DETAILS 
Mice. All animal protocols were approved by and in accordance with the guidelines established 
by the Institutional Animal Care and Use Committee (IACUC), the Laboratory Animal Resource 
Center (LARC) at the University of California San Francisco (UCSF) and the subcommittee on 
Research Animal Care at Massachusetts General Hospital (MGH). Mouse colonies were 
maintained in accordance with National Institutes of Health (NIH), UCSF and MGH guidelines. 
Olig2cre/+, Trp53fl/fl (Mehta et al., 2011), Wnt7a+/- and Wnt7bfl/fl (Stenman et al., 2008) mouse 
lines were intercrossed to generate Olig2cre/+;Trp53fl/fl, Olig2cre/cre;Trp53fl/fl and 
Olig2cre/+;Trp53fl/fl;Wnt7a-/-;Wnt7bfl/fl animals. Cdkn2a-/- mice were obtained from the National 
Cancer Institute (NCI) mouse repository. SCID and nude mice were purchased from Taconic and 
Jackson laboratory, and FVB mice from Charles River (Willmingston, MA).  
Human samples. De-identified human brain tumor tissue was acquired via the UCSF Brain 
Tumor SPORE Biospecimen/Pathology Core under the protocol IRB #10-01318 approved by the 
UCSF Human Research Protection Program Committee on Human Research, and via MGH 
under the protocol #2011P002486 approved by the Partners Human Research Committee and 
MGH Institutional Review Board. Informed consent was obtained from all subjects under the 
existing consent for the UCSF Brain Tumor SPORE Biospecimen/Pathology Core and MGH 
Tissue Bank Core. Upon excision, the tissue samples were immediately snap frozen in liquid 
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nitrogen and stored at -80°C or fixed in 10% buffered formalin, dehydrated through graded 
ethanol, and embedded in Paraplast Plus wax (McCormick Scientific) using standardized 
techniques for pathological analysis.  
METHOD DETAILS 
Cell culture. Glioma neurosphere cultures were established from ganglionic eminences of E14.5 
Olig2cre/+;Trp53fl/fl, Olig2cre/cre;Trp53fl/fl and Olig2cre/+;Trp53fl/fl;Wnt7a-/-;Wnt7bfl/fl embryos and 
from dorsal subventricular zone of P5 Cdkn2a-/- pups. Cells were grown in DMEM/F12 
(Invitrogen) supplemented with penicillin/streptavidin, apotransferrin, progesterone, sodium 
selenite, putrescine, insulin and D-Glucose and passaged once a week. Cultures were grown in 
the presence of EGF and bFGF (20 ng/mL each). Cells were infected with retroviral human 
EGFRvIII, as previously described (Mehta et al., 2011). MGG8 and MGG6, cell lines derived 
from GBM patients, were previously established in the Department of Neurosurgery at 
Massachusetts General Hospital (MGH) (Wakimoto et al., 2012). MGG8 and MGG6 cells were 
grown in serum-free conditions using the NeuroCult NS-A proliferation kit (STEMCELL 
Technologies) and were negative for mycoplasma using the Mycoalert Plus Mycoplasma 
Detection Kit (Lonza). D54 (aka H54), a cell line derived from a GBM patient, was previously 
established at Duke University Medical Center (Bigner et al., 1981). D54 cells were grown in 
Improved MEM supplemented with Hepes, NaHCO3 and 10% FCS. Human oligodendroglioma 
cells (SF10417) were isolated by Lindsey Jones (Joseph Costello’s, lab, UCSF) from a recurrent 
hypermutated oligodendroglioma, 1p/19q codeleted and IDH1R132H mutant (the patient was 
treated with TMZ). Cells were grown in serum-free conditions using the NeuroCult NS-A media 
(STEMCELL Technologies) supplemented with L-Glutamine, B27, N2, Sodium Pyruvate and 
Pen/Strep in the presence of growth factors (bFGF, EGF, PDGFAA). 
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Western blot. Total cell lysate was collected from cells in RIPA buffer supplemented with 
proteinase and phosphatase inhibitor cocktails (Roche), resolved by SDS-PAGE, and then 
immunoblotted using standard techniques. Primary antibodies are listed in the Key Resources 
Table.   
Quantitative RT-PCR. Total RNA was isolated from Olig2cre/+;Trp53fl/fl;hEGFRvIII and 
Olig2cre/cre;Trp53fl/fl;hEGFRvIII tumors at the time of neurological symptoms appearance (n=3 
per genotype) and cells in culture using Trizol reagent (Invitrogen). RNA was cleaned up with an 
RNeasy Kit (Qiagen) and DNAse-digested to remove DNA contamination. 100-500 ng of 
purified RNA was retro-transcribed using the High Capacity RNA to cDNA Master Mix 
(Applied Biosystems). qPCR was performed by using SYBR Green master mix (Roche) in 
Lightcycler 480 (Roche) with specific primers designed for amplicons of 75-150 bp using Primer 
3. Primer sequences are listed in Table S5. Rn18s, GADPH and Actb were used as reference 
genes and experiments were performed in duplicates for each sample.  
In vitro treatment with LGK974 or B20. MGG8 or MGG6 patient-derived cells were cultured 
in NeuroCult NS-A proliferation kit (STEMCELL Technologies) with 10 PM of LGK974 
(Selleckchem, S7143) diluted in DMSO (Wickstrom et al., 2015) or 50 Pg/ml of the anti-VEGF 
B20 (Lu et al., 2012) for 72 hr. Then mRNA was extracted and RT-PCR performed as described 
above. 
Microarray samples preparation. Total RNA from eight tumor samples (4 
Olig2cre/+;Trp53fl/fl;hEGFRvIII and 4 Olig2cre/cre;Trp53fl/fl;hEGFRvIII tumors) were shipped on 
dry ice to the University of California, Los Angeles (UCLA) Neurogenomics Core facility (Los 
Angeles, CA) for analysis using the Illumina MouseRef-8 v2.0 expression BeadChip microarrays 
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(25 697 probes). Amplification was performed using the Ambion TotalPrep RNA amplification 
kit (Life Technologies Inc, Carlsbad, CA). Raw bead-level data were minimally processed by the 
UCLA Neurogenomics Core facility (no normalization or background correction) using 
BeadStudio software (Illumina, San Diego, CA). 
Chromatin Immunoprecipitation Assays. Neurosphere cultures (~107 cells) were fixed with 
1% formaldehyde in phosphate-buffered saline and then lysed, sonicated, and 
immunoprecipitated as previously described (Schmidt et al., 2009). Immunoprecipitations were 
performed using antibodies against Olig2 (DF308, Stiles laboratory), p53 (Santa Cruz, FL393) 
and H3K27ac (Abcam, ab4729). Precipitated DNA was analyzed using real-time quantitative 
PCR using specific primers for Olig2 and p53 binding sites at the Wnt7b locus. Primer sequences 
are available upon request. Motif analysis of p53 and Olig2 binding sites (related to Figure 3): 
p53 consensus binding site: RRRC(A/T) (A/T) GYYY (0-13 bp); p53 binding site upstream of 
Wnt7b: GGGCAAGGCTCCGCCTCTAGACA (~50 kb upstream); Olig2 binding site upstream 
of Wnt7b: CAGCTG, CAAATG and CATCTG (~30 kb upstream). 
Organotypic explants and time-lapse imaging. Brains from P20-P35 FVB mice were dissected 
and put in cold aCSF. 15 µl of isolectin GS-IB4 (Molecular Probes) was added to each well used 
for live-imaging. Brains were cut into slices using vibratome (at the border between rostral 
hippocampus and cortex caudally, and rostrally at ~1 mm caudal of olfactory bulbs). After 
sectioning, slices were washed once in aCSF and once in cell culture media (Hansen et al., 2010) 
and then transferred to the membranes. Olig2cre/+;Trp53fl/fl;hEGFRvIII,  
Olig2cre/+;Trp53fl/fl;Wnt7a-/-;Wnt7bfl/fl;hEGFRvIII, Cdkn2a-/-;hEGFRvIII and patient-derived 
SF10417 cells,  infected with adeno-GFP virus (Vector Labs, 1060) 48 hr before transplantation, 
were injected into the slices using a Hamilton syringe (one injection of 2-3 µl cell 
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suspension/striatum) and plates were incubated for 2 hr at 37°C. GPCs were infected with adeno-
GFP virus (ad:GFP) 48 hr before organotypic transplantation and live-imaging. To label the 
vasculature, Isolectin B4 (IsoB4) was added in the slice culture media. For Wnt inhibition 
experiments, DMSO, 0.1 PM XAV939 (Tocris Bioscience, 284028-89-3) or 1 PM LGK974 
(Selleckchem, S7143) was added to the cells before transplantation. Of note, we treated with 0.1 
PM XAV939, which modulates Wnt in normal OPCs but does not cause cell death (Fancy et al., 
2011). Z-stack images were taken every 15-30 min over a time period of 12-24 hr. After 8-12 hr, 
z positions were readjusted to compensate for tissue movements. At the end of the recording 
period, sections were processed for immunohistochemistry. Imaging files from individual 
acquisitions were compiled and analyzed using Imaris Image Analysis software (v7.6-8.2, 
Bitplane) and annotated using Imaris and ImageJ (U.S. National Institutes of Health, Bethesda, 
Maryland) software. 
Longitudinal intravital microscopy (IVM). In vivo multiphoton laser scanning microscopy 
(MPLSM) analysis of vessels and MGG8 or D54 cells was performed on chronic cranial 
window-bearing three to four month-old male nude mice or Tie2P-GFP Rag1-/- mice. To implant 
transparent cranial windows, a 6 mm circle was drawn over the frontal and parietal regions of the 
skull bilaterally. Using a high-speed air-turbine drill with a burr-tip 0.5 mm in diameter, a groove 
was made on the margin of the drawn circle, until the bone flap becomes loose. The bone flap 
was separated from the dura mater underneath. The dura and arachnoid membranes were cut 
completely from the surface of both hemispheres, avoiding any damage to the sagittal sinus. The 
window was sealed with a 7 mm cover glass, glued to the bone with histocompatible 
cyanoacrylate glue. Ten days after, the cover glass was removed and 1 μl of 20 000 MGG8-GFP-
GLuc or D54-GFP-GLuc cells were stereotactically and slowly injected with a 28-gauge micro-
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syringe and a new cover glass was glued. For intravital microscopy, the animal were anesthetized 
with isoflurane and fixed with metal ring upper frontal tooth holder and a bilateral plastic ear 
holder. The MPLSM consisted of a MilleniaX pumped Tsunami Ti:sapphire laser (Spectra-
Physics). Two-photon excitation of TAMRA, GFP and second-harmonic generation (SHG) beam 
was achieved using 810 nm light, while in the Tie2P-GFP/MGG8-mCherry setup we performed 
sequential imaging using 730 nm and 930 nm lights. Power at the sample was estimated to be 1–
3 mW. MPLSM microscope consisted of an Olympus Fluoview FV300 system customized for 
multiphoton imaging. We performed vessel angiography after retro-orbital injection of 0.1 ml of 
10 mg/ml dextran-TAMRA (500 kDa; in-house conjugated). The images shown are 3D 
rendering of high-resolution z-stacks: 706×706 μm (xy-voxel of 0.69) and at least 60 μm of z-
stack (z-steps 2 μm). We segmented and rendered vessels and tumor cells using a semi-
automated algorithm (Bitplane Imaris Image Analysis software). The longitudinal studies were 
performed every 3-4 days. 
LGK974 in vivo measurement. Three to four months old male nude mice were treated by 
gavage with 5 mg/kg of LGK974 (Selleckchem, S7143) dissolved in 0.5% Tween-80 0.5% 
methylcellulose 3, 6, 9, 12 hr before euthanasia. At described times, we first collected plasma 
and then harvested brain and liver after heart-perfusion with PBS, to avoid traces of the drug in 
the remaining blood. LGK974 was quantified by HPLC analysis (3 mice per time-point).   
Systemic LGK974 treatment protocol for intravital microscopy. Three to four months old 
male nude mice bearing cranial window were transplanted with 20 000 MGG8-GFP-GLuc cells. 
One day after implantation, we performed IVM, randomized mice and started treatments (day 0). 
Mice were treated by gavage with 5 mg/kg of LGK974 (Selleckchem, S7143) in 0.5% Tween-80 
0.5% methylcellulose or vehicle twice a day, for a total of 15 injections when mice actually 
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started showing rapid body weight loss. Administration of 5 mg/kg by gavage twice a day was 
toxic for long-period treatments, causing massive body weight loss and diarrhea in 80% of the 
treated mice after 10 days. IVM was also performed at day 4 and day 8 from the beginning of the 
treatment. The quantification of MGG8-GFP-GLuc cells in contact with the vessels was 
performed on 3D rendering of high-resolution z-stacks – 706×706 μm (xy-voxel of 0.69) and at 
least 60 μm of z-stack (z-steps 2 μm) – of regions of interests at the border of the tumor masses. 
We did not consider big masses (more than 100 μm in diameter) of tumor cells. In order to 
quantify only the tumor cells integrated in the brain and avoid the superficial cells, we used 
second-harmonic generation (SHG) beam – present at the border of the brain – as a reference. 
The presented result is based on n = 2 experiments, in total n = 9 mice for vehicle cohort and n = 
7 mice for LGK974 cohort, at least 3 regions of interest per mouse, cells manually counted in a 
double blinded manner (n = 13 994 in total).  
Toxicity studies for LGK974 dosage. In order to investigate toxicity of LGK974 treatment, we 
first examined the effect of different doses in nude mice. Mice were treated by gavage with 
LGK974 (Selleckchem, S7143) in 0.5% Tween-80 0.5% methylcellulose or vehicle. We found 
that 5 mg/kg twice a day (dosage used for the intravital imaging study) was toxic if given long-
term, inducing body weight loss and diarrhea. In contrast, 5 mg/kg once a day was tolerated for 
up to 28 days in 80% of mice (dosage then used for the survival studies).  
Systemic LGK974 treatment protocol for survival studies. Treatment for survival studies was 
performed with a 5 mg/kg by gavage once a day of LGK974. In the case of LGK974 alone 
(Figure S5E), treatment was initiated at day 12 after orthotopic implantation of 20 000 MGG8-
GFP-GLuc cells, corresponding to a median blood Gluc activity of 7 400 ± 4 900 RLU/s, 
equivalent to MGG8 tumor volumes of around 4 mm3 (Kloepper et al., 2016). In case of 
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combinatorial survival study (Figure 6F), treatment was initiated at day 36 after orthotopic 
implantation of 200 000 MGG8 cells, corresponding to a median blood Gluc activity of 435 000 
± 29 000 RLU/s, equivalent to MGG8 tumor volumes of around 9-10 mm3 (Kloepper et al., 
2016). In both studies, mice were randomized by pre-treatment GLuc activity and body weight. 
MGG8-bearing nude mice were treated with vehicle (0.5% Tween-80 and 0.5% Methylcellulose; 
Sigma) and PBS; vehicle + TMZ (2.5 mg/kg) in PBS; PBS + LGK974 (5 mg/kg) in 0.5% 
Tween-80 and 0.5% Methylcellulose; or TMZ + LGK974. LGK974 or vehicle was administered 
by gavage daily. TMZ or PBS were administered i.p daily for 5 consecutive days. Animals were 
treated until they were killed because of the occurrence of lethargy, body weight loss of >20%, 
or impairing neurological symptoms. 
In vivo primary mouse cells transplants. Olig2cre/+;Trp53fl/fl;hEGFRvIII (Olig2+ tumors), 
Olig2cre/cre;Trp53fl/fl;hEGFRvIII (Olig2- tumors), Olig2cre/+;Trp53fl/fl;Wnt7a-/-
;Wnt7bfl/fl;hEGFRvIII (Wnt7a/b-null tumors) and Cdkn2a-/-;hEGFRvIII tumor cells were grown 
in culture and transplanted into the brains of SCID mice as previously described (Mehta et al., 
2011), at the following coordinates, according to Bregma: 1 mm (anterior), 2 mm (lateral), 2.5 
mm (deep). 2 x 105 cells in Hanks’ Balanced Salt Solution without Ca2+ and Mg2+ (HBSS) were 
manually injected into the striatum. Animals were sacrificed upon development of neurological 
deficits for all experiments except invasion experiments where animals were sacrificed at one-
month post-transplantation (Figure 1D; Figure 2D (right panel); Figure S1C; Figure S1I). 
Bevacizumab-Resistant xenograft models. As described in (Jahangiri et al., 2013), 500 000 
U87 cells were implanted subcutaneously in combination with 1:1 matrigel in 20 nude mice. 15 
of the animals were treated with Bevacizumab at 10 mg/kg twice a week while the control cohort 
of 5 mice was treated with equal concentrations of humanized IgG. The first tumor from each 
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treatment arm to reach 2 cm in any diameter was resected, dissociated and re-implanted in a new 
generation of 5 mice. This was repeated for nine generations creating the Bev-Resistant and Bev-
Sensitive cell lines. For the intracranial studies, the largest tumor of the 9th generation were then 
taken, and implanted intracranially at a concentration of 250 000 cells. Similarly, these animals 
received the same concentration of treatment as their subcutaneous donors. Animals were 
sacrificed upon development of neurological deficits or signs of decompensation or cachexia.  
Each mouse was perfused transcardially with PBS and the tumor was dissected under a surgical 
microscope, lysed and prepared for immunoblotting. 
Immunohistochemistry. For human tissue analysis, sections were fixed 5 min in 4% 
paraformaldehyde, rinsed in PBS 0.1% Triton-5% Horse serum and incubated overnight at 4°C 
with primary antibodies in PBS 0.1% Triton-5% Horse serum. Sections were then rinsed several 
times in PBS 0.1% Triton-5% Horse serum and incubated with the secondary antibodies in PBS 
0.1% Triton-5% Horse serum for 30 min. Sections were rinsed and mounted using DAPI 
Fluoromount-G. Mouse brains were perfused with 4% paraformaldehyde, rinsed in phosphate 
buffer saline (PBS) pH 7.2 for 1 hr. Brains were cryoprotected in 30% sucrose and embedded in 
OCT (TissueTek, Sakura). 14 µm cryostat sections were used for immunohistochemical staining. 
Sections were incubated overnight at 4°C with the primary antibodies in PBS 0.1% Triton-1% 
Horse serum. Sections were then rinsed several times in PBS 0.1% Triton-1% Horse serum and 
incubated with the secondary antibodies in PBS 0.1% Triton-1% Horse serum for 30 min. 
Sections were rinsed and mounted using DAPI Fluoromount-G. Primary antibodies are listed in 
the Key Resources Table.  
Image acquisition. Confocal images were obtained using a Leica SP5 AOBS Upright 
Microscope. Brightfield and fluorescence acquisition was realized using a Zeiss Axioskop2 
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microscope coupled to an AxioCam HRc camera. Images in Figure S4 were acquired with a 
Zeiss AxioImager 2 upright epifluorescence microscope with a motorized Ludl stage (Zeiss). 
Mosaic TIFF images of stained tissue sections were generated using the TissueFAXS software 
(TissueGnostics, Vienna, Austria). 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Microarray data processing. Preprocessing of data was performed within the R statistical 
computing environment. The SampleNetwork (Oldham et al., 2012) R function was used to 
determine outlying samples, assess technical batch effects, and perform data normalization. Two 
mice died before the end of the time course. These samples were removed, leaving three samples 
in each group. Following removal of outlying samples and quantile normalization (Bolstad et al., 
2003), differential expression analysis was performed to identify genes that were significantly 
up- or down-regulated in Olig2- tumors relative to Olig2+ tumors (three samples per group). 
Probes on the microarray that were detected above background levels in at least one sample 
(n=17 078) were included in the analysis. Differential expression analysis was performed on 
expression data using the bayes.t.test R function. The p values were adjusted to account for 
multiple testing using the false discovery rate (FDR) approach, and probes with FDR p < 0.05 
were considered to be differentially expressed. Genes up-regulated in Olig2+ tumors were 
compared to murine OPCs (versus astrocytic), human oligodendroglioma and GBM subtypes 
using published dataset (Tirosh et al., 2016; Verhaak et al., 2010; Wang et al., 2017; Zhang et al., 
2014). Hierarchical clustering was performed using Gene Cluster 3.0 (de Hoon et al., 2004) and 
Treeview (Saldanha, 2004).  
The Cancer Genome Atlas data processing. Normalized (level 3) data were obtained for GBM 
(microarray) and oligodendroglioma (RNAseq) groups through the TCGA data portal 
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(https://tcga-data.nci.nih.gov/tcga/). In some cases multiple samples were associated with a 
single patient ID. Since replicate samples from a single patient might bias pairwise correlations, 
patient IDs with multiple associated samples were removed from the analysis. Technical batch 
effects were assessed using the SampleNetwork R function (Oldham et al., 2012). Technical 
batch effects associated with “bcr_batch” and “A260:A280” were identified in the GBM data 
and corrected with sequential rounds of the ComBat (Johnson et al., 2007) function from the 
sva R package. No other technical batch effects were identified and no additional normalization 
was performed. Tumors carrying mutations in TP53 were identified using the curated .maf file 
from the oligodendroglioma exome sequencing data. Pairwise Pearson correlation coefficients 
(r) were calculated between genes within each group using log2-transformed expression values. 
Barplots of pairwise correlations were produced using the ggplot2 R package (Figure 4A-C 
and Figure S3) and heatmaps were produced using the labeledHeatmap function from the 
WGCNA R package (Langfelder and Horvath, 2008) (Figure S3).  
Allen Brain Institute data processing. RNAseq data from two human adult brains (H0351.2001 
and H0351.2002) were obtained through the Allen Brain Institute (ABI) data portal. The raw 
reads were taken as input for the SampleNetwork R function (Oldham et al., 2012) and the data 
were quantile normalized (Bolstad et al., 2003). Technical batch effects were assessed and a 
batch effect associated with “rnaseq_run_id” was identified and corrected with the ComBat 
function in the sva R package. After correcting for rnaseq_run_id six outlying samples 
(S020722, S020656, S010416, S010536, S020697, S010508) with standardized sample 
connectivities < –3  were identified and removed (Oldham et al., 2012). A batch effect associated 
with “RIN” was revealed and corrected with the ComBat function as before. No further 
normalization was performed. Pairwise Pearson correlation coefficients were calculated between 
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genes using log2-transformed data across cortical samples from the frontal, parietal and occipital 
lobes (n = 152). 
Statistical analysis of pairwise correlations. All statistical analysis was performed within the R 
statistical computing environment. To assess whether pairwise Pearson correlation coefficients 
(r) between genes showed a significant difference between groups they were first rescaled using 
Fisher’s r-to-z transformation: 
 
where k indexes the groups being compared. The intergroup difference between the resulting z-
scores (zdiff) (e.g. for groups 1 and 2) was divided by the joint standard error: 
 
where n1 and n2 denote the number of samples in group 1 and 2, respectively. The significance 
level of zdiff (p value) was then calculated based on the standard normal distribution (Oldham et 
al., 2012). 
Vasculature and imaging metrics analysis. Quantifications of density (MVD, vessel/mm2), 
size, area (percentage of vascular area) and lumen of CD31 (endothelial cells) positive vessels, 
and basement membrane coverage (Collagen IV) were performed using in-house segmentation 
ImageJ algorithms (U.S. National Institutes of Health, Bethesda, Maryland) on 40X normal and 
tumor fields (five to eight per animal) from Olig2cre/+;Trp53fl/fl;hEGFRvIII (Olig2+ tumors), 
Olig2cre/cre;Trp53fl/fl;hEGFRvIII (Olig2- tumors), Olig2cre/+;Trp53fl/fl;hEGFRvIII (Wnt7a/b WT 
tumors) and Olig2cre/+;Trp53fl/fl;Wnt7a-/-;Wnt7bfl/fl;hEGFRvIII (Wnt7a/b-null tumors) transplanted 
animals (n = 3-4 per genotype). Quantification of fibrinogen staining was performed using the 
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Integrated Density function from ImageJ (U.S. National Institutes of Health, Bethesda, 
Maryland) on 20X normal and tumor fields (n = 3 animals per genotype). Quantifications of 
Iba1+ microglia numbers, cell perimeter (Pm) and soma cell size (area, Pm2) were performed 
using ImageJ (U.S. National Institutes of Health, Bethesda, Maryland) on 20X normal and tumor 
fields (n = 3 animals per genotype). Quantifications of the proliferative index (Ki67+ tumor cells) 
were performed on 10X fields from Olig2cre/+;Trp53fl/fl;hEGFRvIII (Olig2+ tumors) and  
Olig2cre/cre;Trp53fl/fl;hEGFRvIII (Olig2- tumors) transplanted animals (n = 3 animals per 
genotype). Quantifications of Ki67+ CD31+ cells were performed on 20X fields from 
Olig2cre/+;Trp53fl/fl;hEGFRvIII (Olig2+ tumors) and  Olig2cre/cre;Trp53fl/fl;hEGFRvIII (Olig2- 
tumors) transplanted animals (n = 3 animals per genotype). Quantifications of Lef1+ CD31+ cells 
were performed on 20X normal and tumor fields from Olig2cre/+;Trp53fl/fl;hEGFRvIII (Olig2+ 
tumors) and  Olig2cre/cre;Trp53fl/fl;hEGFRvIII (Olig2- tumors) transplanted animals (n = 3 per 
genotype) and human oligodendroglioma and glioblastoma samples (n = 3 cases each). 
Quantifications of hEGFR+ DAPI+ cells per 100 Pm vessel were performed on 40X tumor fields 
at the invasion border from Olig2cre/+;Trp53fl/fl;hEGFRvIII (Wnt7a/b WT tumors) and 
Olig2cre/+;Trp53fl/fl;Wnt7a-/-;Wnt7bfl/fl;hEGFRvIII (Wnt7a/b-null tumors) transplanted animals (n 
= 3 per genotype). Olig2, Lef1 and Wnt7 stained areas were normalized with DAPI or GFP areas 
to quantify the percentage of stained areas within the MGG8 tumors (n = 4 mice). VEGF in 
LGK974-treated tumors was analyzed by quantifying the percentage of area with VEGF staining 
within the whole tumor (n = 3 per treatment, size- and time-matched tumors). Iba1+ cells were 
counted within the whole are of the tumor in LGK974 or vehicle-treated mice (n = 3 per 
treatment, size- and time-matched tumors).  
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Statistical Analysis. Unless otherwise specified, data are presented as mean ± s.e.m. Student's 
two-tailed t test based on Gaussian distributions were used to assess the significance. Blinding 
during analysis was used for all the in vivo experiments. Statistics were performed using 
Graphpad Prism and Microsoft Excel software. 
DATA AND SOFTWARE AVAILABILITY 
Accession Codes. Microarray data are deposited in the NCBI Gene Expression Omnibus (GEO). 
The accession number is GSE110052. 
 
SUPPLEMENTARY TABLE LEGENDS 
Table S1. Gene Ontology analysis of genes enriched in Olig2+ and Olig2- tumors, Related to 
Figure 1.            
Table S2. Hierarchical clustering analysis of genes enriched in mouse OPC versus astrocytes 
(Zhang et al., 2014), human oligodendroglioma (Tirosh et al., 2016) and human proneural, 
classical and mesenchymal GBMs (Wang et al., 2017), comparing Olig2+ and Olig2- tumors, 
Related to Figure 1. 
Table S3. Pearson correlation p values and adjusted p values (q values), Related to Figure 4. 
Table S4. Patient characteristics and blinded manual scoring of Wnt7a staining, Related to 
Figure 7.       
Table S5. Primers sequences used for quantitative PCR.      
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-b actin Sigma-Aldrich Cat# A5316; RRID: 
AB_476743 
Mouse monoclonal anti-b catenin Millipore Cat# 05-665; RRID: 
AB_309887 
Mouse monoclonal anti-alpha tubulin  Sigma-Aldrich Cat# T5168; RRID: 
AB_477579 
Mouse monoclonal anti-b tubulin Sigma-Aldrich Cat# T4026; RRID: 
AB_477577 
Rabbit polyclonal anti-CD31 Abcam Cat# ab28365; 
RRID: AB_726365 
Rat monoclonal anti-CD31 BD Biosciences Cat# 550274; RRID: 
AB_393571 
Goat polyclonal anti-Collagen IV Millipore Cat# ab769; RRID: 
AB_92262 
Mouse monoclonal anti-human EGFR Dako Cat# M7298; RRID: 
AB_2286187 
Sheep polyclonal anti-fibrinogen Abcam Cat# ab118533; 
RRID: AB_10900171 
Mouse monoclonal anti-GADPH Abcam Cat# ab8245; RRID: 
AB_2107448  
Chicken polyclonal anti-GFP Aves Lab GFP-1020; RRID: 
AB_10000240 
Rabbit polyclonal anti-GFAP Dako Cat# Z0334; RRID: 
AB_10013382 
Rabbit polyclonal anti-Histone H3 (acetyl K27) Abcam Cat# ab4729; RRID: 
AB_2118291 
Mouse monoclonal anti-HLA Class 1 ABC Abcam Cat# ab70328; 
RRID: AB_1269092 
Rabbit polyclonal anti-Iba1 Wako Cat# 019-19741; 
RRID: AB_839504 
Mouse monoclonal anti-Idh1-R132H Dianova Cat# DIA-H09; 
RRID: AB_2335716 
Rabbit polyclonal anti-Ki67 Thermo Scientific Cat# RM-9106; 
RRID: AB_2341197 
Rabbit monoclonal anti-Lef1 Cell Signaling Cat# 2230; RRID: 
AB_823558 
Rabbit polyclonal anti-LYVE1 Novus Biologicals Cat# NB100-725; 
RRID: AB_10003273 
Rabbit polyclonal anti-NG2 Millipore Cat# AB5320; RRID: 
AB_91789 
Mouse monoclonal anti-Nkx2.2 DSHB Cat# 74.5A5; RRID: 
AB_531794 
Mouse monoclonal anti-Olig2 Charles D. Stiles, 
Harvard Medical 
School, Cambridge, 
Massachusetts 
 
Rabbit polyclonal anti-Olig2 Millipore Cat# AB9610; RRID: 
AB_570666 
Key Resource Table
 Rabbit polyclonal anti-Olig2 Charles D. Stiles, 
Harvard Medical 
School, Cambridge, 
Massachusetts 
DF308; RRID: 
AB_2336877 
Rabbit polyclonal anti-p53 Santa Cruz Cat# FL-393; RRID: 
AB_653753 
Rat monoclonal anti-CD140a BD Biosciences Cat# 558774; RRID: 
AB_397117 
Rabbit monoclonal anti-Tcf4 Cell Signaling Cat# 2569S; RRID: 
AB_2199816 
Mouse monoclonal anti-VEGF Thermo Fisher Cat# MS-1467; 
RRID: AB_144688 
Rabbit polyclonal anti-vWF Abcam Cat# ab6994; RRID: 
AB_305689 
Goat polyclonal anti-Wnt7a Santa Cruz Cat# sc-26361; 
RRID: AB_2215743 
Rabbit polyclonal anti-Wnt7a Abcam Cat# ab100792; 
RRID: AB_10858110 
Rabbit polyclonal anti-Wnt7b Abcam Cat# ab94915; 
RRID: AB_10675749 
Bacterial and Virus Strains  
eGFP adenovirus Vector Biolabs Cat# 1060 
GFP-GLuc lentivirus  Wurdinger et al. 2008  
mCherry lentivirus Massachusetts 
General Hospital Viral 
Vector Core Facility 
 
   
   
   
Biological Samples   
Human grade III oligodendroglioma and proneural 
GBMs 
The Brain Tumor 
SPORE 
Biospecimen/Patholog
y Core, University of 
California San 
Francisco 
http://cancer.ucsf.ed
u/research/spores/br
ain-spore/cores#one 
Paired pre-Bev (biopsies) and post-Bev (autopsies) 
GBMs 
Tissue Bank Core, 
Mass General Hospital 
 
Human primary GBMs flash-frozen tissue Tissue Bank Core, 
Mass General Hospital 
 
   
   
Chemicals, Peptides, and Recombinant Proteins 
XAV-939 Tocris Bioscience Cat# 3748; CAS: 
284028-89-3 
LGK-974 Selleckchem Cat# S7143; CAS: 
1243244-14-5 
B20-4.1 Genentech/Hoffmann 
La-Roche 
 
Bevacizumab Genentech CAS:   
216974-75-3 
Temolozomide Tocris Bioscience CAS: 85622-93-1   
Critical Commercial Assays 
    
   
   
   
   
Deposited Data 
Raw and analyzed data This paper GEO: GSE110052 
TCGA data portal TCGA https://tcga-
data.nci.nih.gov/tcga
/ 
Allen Brain Institute data portal ABI http://human.brain-
map.org/static/downl
oad 
   
   
Experimental Models: Cell Lines 
Human: MGG8 cells Wakimoto et al., 2012  
Human: MGG6 cells Wakimoto et al., 2012  
Human: D-54 cells Bigner et al., 1981 RRID:CVCL_7185 
Human: U-87MG ATCC cells ATCC Cat# 
300367/p658_U-
87_MG, 
RRID:CVCL_0022 
Human: SF10417 cells Joseph Costello, 
University of California 
San Francisco 
 
Experimental Models: Organisms/Strains 
Mouse: Olig2tm2(TVA,cre)Rth/J The Jackson 
Laboratory 
RRID:IMSR_JAX:01
1103 
Mouse: FVB.129-Trp53tm1Brn/Nci NCI RRID:IMSR_NCIMR:
01XC2 
Mouse: B6;129S1-Wnt7atm1Amc/J The Jackson 
Laboratory 
RRID:IMSR_JAX:00
4715 
Mouse:  B6;129X1-Wnt7btm2Amc/J The Jackson 
Laboratory 
RRID:IMSR_JAX:00
8467 
Mouse: B6.129-Cdkn2atm1Rdp/Nci NCI RRID:IMSR_NCIMR:
01XB1 
Mouse: TieP-GFP Rag1-/- Cheng  et al, 2011  
Mouse: IcrTac:ICR-Prkdcscid Taconic RRID:IMSR_TAC:icr
sc 
Mouse: NOD.CB17-Prkdcscid/J The Jackson 
Laboratory 
RRID:IMSR_JAX:00
1303 
FVB/NCrl Charles River RRID:IMSR_CRL:20
7 
Oligonucleotides 
Primers for mouse Lef1, LYVE-1, Plvap, Slc2a1, Prox1, 
Tbx1, VEGFR1/2/3, Wnt5a, Wnt7a/b, Vegfa/b/c, see 
Table S5  
This paper N/A 
Primers for mouse Lef1, LYVE-1, Plvap, Slc2a1, Prox1, 
Tbx1, VEGFR1/2/3, Wnt5a, Wnt7a/b, Vegfa/b/c, see 
Table S5 
This paper N/A 
   
    
   
Recombinant DNA 
   
   
   
   
   
Software and Algorithms 
R package  http://cran.us.r-
project.org 
Gene Cluster 3.0 De Hoon et al., 2004 RRID:SCR_002250 
Imaris v7.6-8.2 Bitplane RRID:SCR_007370 
Java Treeview Saldanha, 2004 RRID:SCR_013503 
   
Other 
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Figure 4 Click here to download Figure Griveau, Seano et al-Cancer Cell-
Figure 4.tif
Figure 5 Click here to download Figure Griveau, Seano et al-Cancer Cell-
Figure 5.tif
Fi
gu
re
 6
C
lic
k 
he
re
 to
 d
ow
nl
oa
d 
Fi
gu
re
 G
riv
ea
u,
 S
ea
no
 e
t a
l-C
an
ce
r C
el
l-F
ig
ur
e 
6.
tif
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1Figure S1. Characteristics of Olig2+ and Olig2- tumors, Related to Figure 1
(A) Immunostaining for Olig2 and GFAP and counterstaining with Hematoxylin of
tumors from SCID mice transplanted with Olig2+ and Olig2- cells (n = 3 animals per
genotype). Scale bars, 20 m.
Supplemental Text and Figures Click here to download Supplemental Text and Figures Griveau,
Seano et al-Cancer Cell-SI.pdf
2(B) Immunostaining for PDGFRand GFAP of tumors from SCID mice transplanted
with Olig2+ and Olig2- cells (n = 3 animals per genotype). Yellow and white arrowheads
indicate PDGFR-and GFAP-positive cells, respectively. Scale bars, 10 m.
(C) Immunostaining for hEGFR, NG2 and GFAP of tumors from SCID mice transplanted
with Olig2+ and Olig2- cells (n = 3 animals per genotype). Yellow and white arrowheads
indicate hEGFR+ NG2+ and hEGFR+ GFAP+ cells, respectively. Scale bars, 10 m.
(D) Immunostaining for Ki67 and counterstaining with Hematoxylin of tumors from
SCID mice transplanted with Olig2+ and Olig2- cells (n = 3 animals per genotype).
Quantifications of the percentage of Ki67+ tumor cells (proliferative index). Data are
mean ± s.e.m (n = 3 experiments, ns: non-significant). Scale bars, 20 m.
(E) Unbiased hierarchical clustering analysis of genes upregulated in Olig2+ versus
Olig2- tumors (FDR adjusted p < 0.05). Heatmap represents log2 fold change (n = 3
samples per genotype).
(F) Hierarchical clustering analysis of oligodendrocytic specific genes enriched in human
oligodendroglioma, comparing Olig2+ versus Olig2- tumors (FDR adjusted p < 0.05).
Heatmap represents log2 fold change (n = 3 samples per genotype).
(G) Analysis of genes enriched in human proneural and mesenchymal GBMs, comparing
Olig2+ to Olig2- tumors (FDR adjusted p < 0.05). Heatmap represents log2 fold change (n
= 3 samples per genotype).
(H) Quantitative PCR comparing Olig2- to Olig2+ tumors. Rn18s was used as
housekeeping gene. Data are mean ± s.e.m (n = 3 experiments).
(I) Immunostaining for hEGFR and CD31 of tumors from SCID mice transplanted with
Olig2+ and Olig2- cells and analyzed one month after transplantation (n = 3 animals per
3genotype). No evidence of hEGFR+ CD31+ “trans-differentiated cells” could be found.
Scale bars, 50 µm.
(J) Quantitative PCR comparing Olig2- to Olig2+ tumors. Rn18s was used as
housekeeping gene. Data are mean ± s.e.m (n = 3 experiments).
(K) Immunostaining for Iba1, depicting a resting cell (left) and activated cells (right) and
quantification of Iba1+ cell density in Olig2+ and Olig2- tumors. The cell density was
normalized to the normal brain. Data are mean ± s.e.m (n = 3 animals per genotype, **p
< 0.01). Scale bars, 25 m.
See also Table S2
4Figure S2. Increased Wnt signaling versus angiogenic signaling in Olig2+ and Olig2-
tumors, respectively, Related to Figure 2
(A) Immunostaining for Wnt7a, Wnt7b, hEGFR, Nkx2.2 and CD31 proteins in Olig2+
tumors in OPCL cells (yellow arrowheads). n = 3-4 animals per genotype. Scale bars, 10
μm.
(B) Immunostaining for CD31 and Lef1 (white arrowheads) in vessels from Olig2+ and
Olig2- tumors (quantified on the right). Data are mean ± s.e.m (n = 3 experiments, *p <
50.05). Scale bar, 10 μm. Immunostaining for -catenin and CD31 using tumors from
SCID mice transplanted with Olig2+ cells. Scale bar, 25 µm.
(C) Gene expression analysis of angiogenesis genes upregulated in Olig2- compared to
Olig2+ tumors (FDR adjusted p < 0.05). Data (log2 fold change) are mean ± s.e.m (n = 3
animals per genotype).
(D) Quantitative PCR using lymphatic vessels specific markers comparing Olig2+ to
Olig2- tumors. Rn18s and Actb were used as housekeeping genes. All data are mean ±
s.e.m (n = 3 animals per genotype and two duplicates per sample).
(E) Immunostaining for collagen IV (Col IV), LYVE-1 and CD31 in Olig2- tumors,
showing no LYVE-1 expression in the vessels (n = 3-4 animals per genotype). Scale bar,
100 µm.
(F) Immunostaining for GFP, Isolectin B4 (IsoB4) and Olig2 on slices transplanted with
Olig2+ cells. Scale bar, 10 µm.
6
7Figure S3. WNT7 expression in human gliomas, Related to Figure 4
(A) Pearson correlation coefficients of NKX2.2, OLIG2 and PDGFRA with WNTs mRNA
levels in oligodendroglioma (OD) and glioblastoma (GBM). n = 188 for OD and n = 539
for GBM.
(B) Heatmaps of Pearson correlation coefficients of stem cell (ABCG2, ITGA6, PROM1),
OPC (NKX2.2, OLIG2, PDGFRA) and WNT7A/B mRNA levels in oligodendroglioma
(OD) and glioblastoma (GBM). n = 188 for OD and n = 539 for GBM.
(C) Western Blot for Wnt7b, -Actin and -tubulin using lysates from primary
glioblastoma (GBMs) and grade III oligodendroglioma (OD).
(D) Quantitative PCR using tumors from grade II (#8245, #8500) and grade III
oligodendroglioma (#8292, #7891). Bars represent the level of expression (Ct), data are
mean ± s.e.m (n = 3 triplicates).
(E-F) Analysis of grade III oligodendroglioma (OD Grade III) (E) and proneural
glioblastoma (PN GBM) (F) using immunostaining for Olig2, vWF, Wnt7a, Wnt7b,
Nkx2.2 and Collagen IV. Scale bars, 20 μm
(G) Analysis of grade III oligodendroglioma (OD Grade III) using immunostaining for
CD31, Lef1, Tcf4, Wnt7a and Ki67. White arrowheads indicate Tcf4+ endothelial cells
(left). Yellow and white arrowheads indicate proliferating cells and vessels, respectively
(right). Scale bars, 10 μm.
See also Table S3
8Figure S4. Characterization of the proneural GBM patient-derived MGG8 cell line,
Related to Figure 6
9(A) Quantitative PCR for OLIG2, WNT7A, and LEF1 using cultured patient-derived cell
lines (MGG8 and D54). GADPH was used as housekeeping gene. Data are mean ± s.e.m.
(n = 2 experiments with technical triplicates, *p < 0.05, **p < 0.01).
(B) Immunostaining for Olig2, Wnt7a, and Lef1 in combination with markers for tumor
cells – GFP or hHLA – on MGG8-GFP-GLuc cells one month after implantation. The
percentage of area covered by Olig2+, Wnt7a+ and Lef1+ cells was quantified. Data are
mean ± s.e.m (n = 3 mice). Scale bars, 50 μm and 20 μm (insets).
(C) 3D renderings of 20 μm-deep z-stacks of of MGG8-GFP-GLuc cells using intravital
imaging. Vessels were visualized using retro-orbital injection of 500 kDa TAMRA-
Dextran (TAMRA-Dex). Days in the legend are from MGG8 cells intracranial
implantation. Insets are high magnifications of the white dashed squares. Scale bars, 50
µm and 25 µm (insets).
(D) Vessel co-option in the invasive front within the cerebellar cortex of MGG8-GFP-
GLuc-bearing mice one month after implantation, labelled with hHLA and CD31. Right
panels represent high magnifications of the white dashed squares. Scale bars, 50 μm.
(E) Immunostaining for GFP and CD31, showing vessel co-option of MGG8-GFP-GLuc
cells at the invasive front within the cerebellar cortex one month after implantation. Scale
bars, 5 μm.
10
Figure S5. Pharmacokinetics and toxicity of LGK974, Related to Figure 6
(A) HPLC analysis of LGK974 (5 mg/kg by gavage) in nude mice in the liver, the plasma
and the brain (left graph). The right graph shows the accumulation of LGK974 in the
brain of treated animals. Data are mean ± s.e.m. (n = 3 per time-point).
(B) Quantification of the intensity of Wnt7a staining in the cerebral cortex from vehicle
or LGK974-treated mice after 8 days of treatment. Data are mean ± s.e.m. (**p < 0.01, n
= 6 mice for vehicle cohort and n = 6 mice for LGK974 cohort).
(C) No difference in body weight was observed after 9 days of 5 mg/kg of LGK974 by
gavage once a day. Data are mean ± s.e.m. (n = 6 mice per group).
(D) Histopathological analysis of the brain, liver, kidney and intestine of vehicle- and
LGK974-treated animals using Hematoxylin/Eosin. Treatment: 5 mg/kg of LGK974 by
gavage once a day (n = 6 mice per group). Scale bars, 100 μm.
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(E) Kaplan-Meier survival curve of vehicle- and LGK974-treated mice. LGK974 (median
survival = 38 days of treatment, n = 10) led to a trend for survival benefit compared with
vehicle (median survival = 34 days of treatment, hazard ratio (HR) 2.64, 95% confidence
interval (CI) 0.93–7.48, **p = 0.06, n = 10).
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Figure S6. Effects of anti-VEGF treatment on OPCL markers and Wnt expression,
Related to Figure 7
(A) Quantitative PCR for VEGFA using DMSO and LGK974-treated MGG6 patient-
derived cells. GAPDH was used as housekeeping gene. Data are mean ± s.e.m. (n = 2
experiments with technical triplicates, *p < 0.05).
(B) Quantitative PCR for OLIG2 using IgG and B20 (anti-VEGF)-treated MGG6 patient-
derived cells. GAPDH was used as housekeeping gene. Data are mean ± s.e.m. (n = 2
experiments with technical triplicates). Student's two-tailed t tests were used to assess the
significance (***p < 0.001).
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(C) Immunoblot for GFAP, Nkx2.2, Olig2, Wnt7a, Wnt7b and GADPH using IgG- and
Bev-treated Bev-sensitive tumors and IgG- and Bev-treated Bev-resistant tumors (n = 4
animals per genotype). Bev: bevacizumab.
Movie S1. Tumor single-cell migration on the vasculature, Related to Figure 2
Time-lapse video in slice culture of P35 cortex, showing the migration of Olig2+ (GFP+)
cells on vessels (in red, labeled with Isolectin B4-Alexa 568). Each frame is at a 30 min
interval.
Movie S2. Migration of Cdkn2a-/-;hEGFRvIII cells on the vasculature, Related to
Figure 5
Time-lapse video in slice culture of P15 cortex, showing the migration of Cdkn2a-/-;
hEGFRvIII (GFP+) cells on vessels (in red, labeled with Isolectin B4-Alexa 568). Each
frame is at a 10 min interval.
Movie S3. Impaired migration of Cdkn2a-/-;hEGFRvIII cells after Wnt signaling
inhibition, Related to Figure 5
Time-lapse video in slice culture of P15 cortex, showing the decrease in migration of
Cdkn2a-/-; hEGFRvIII (GFP+) cells on vessels (in red, labeled with Isolectin B4-Alexa
568) after treatment with 0.1 M XAV939. Each frame is at a 10 min interval.
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